Artiva Biotherapeutics, Inc.
Industry
- Biotechnology
- Gene Therapy, Cell Therapy
- Pharmaceuticals
- Specialty Pharmaceuticals
Latest on Artiva Biotherapeutics, Inc.
With the rapid growth in the global cell and gene therapy (CGT) market, South Korean pharma firms have increasingly been diversifying into the contract manufacturing area for these novel modalities vi
Actuate Therapeutics, Inc. grossed $22.4m from its initial public offering of 2.8 million shares priced at $8 each in the 15th biopharmaceutical company IPO in the US in 2024. It was not the smallest
Artiva Biotherapeutics, Inc. ’s initial public offering late on 18 July reflected the mixed bag that the IPO market has become. To get the offering through the IPO window at a time when first-time off
The number of biopharmaceutical company initial public offerings in the US dropped considerably from the first quarter to the second quarter, but with 12 IPOs during the first half of 2024 the market